cyrilzakka/clinical-trials huggingface dataset:
Investigation of Grip Strength, Pain and Anxiety Levels in Dentists

The aim of the study is to evaluate the relationship between professional experience and grip strength, pain threshold and anxiety level in dentists. As a result of the results obtained, we aim to contribute an original study to the literature and to increase awareness by informing the dentists participating in the study.

Our hypotheses:

H1: Professional experience has an effect on hand grip strength in dentists. H2: Professional experience has an effect on finger grip strength in dentists. H2: Professional experience has an effect on pain in dentists. H3: Professional experience has an effect on anxiety level in dentists.

The unique value of our study is that it is the first study to examine the relationship between dentists' professional experience and grip strength, pain, and anxiety. When we look at the literature, we have not found any studies examining the effect of dentists' professional experience on grip strength and pain. In the study, grip strength, pain threshold, and forearm grip strength will be evaluated. Grip strength will be assessed with a Jamar hand dynamometer, pinch grip with a Baseline brand pinchmeter, pain threshold with a dolorometer, and forearm grip strength with a handheld dynamometer. Anxiety will be assessed with the Beck Anxiety Questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Graduating from the Faculty of Dentistry
* Having 1 year or more professional experience

Exclusion criteria;

* Having received physical therapy from any area in the last 6 months or currently receiving physical therapy,
* Having a congenital musculoskeletal deformity,
* Having a neurological or rheumatic disease,
* Having undergone surgery due to a musculoskeletal disorder.
Trial of Acupuncture Pelvic and Low Back Pain in Pregnancy (Medical and Economical Assessment)

Pelvic girdle and low back pain are common in pregnancy, and cause severe impairment in 10% of women. Our hypothesis is that offering acupuncture in addition to standard care would reduce pain and impairment throughout pregnancy. 300 pregnant women from 5 maternity units will be randomized over a 3 year period to receive standard care or standard care plus acupuncture. Main outcome will be the number of days during pregnancy with maximum pain ≤ 4/10. Secondary outcomes will compare groups for an impairment score and for direct and indirect costs.

Background. Pelvic and low back pain (PLBP) affects 30% of pregnant women for weeks or months, causing severe impairment in 10% of women. Standard treatment, based on pain killers, postural recommendations, exercises, is of limited value. Previous trials showed that adding acupuncture to standard treatment reduces pain and impairment in the short run.

Hypothesis Providing acupuncture to pregnant women with PLBP could reduce pain and impairment throughout pregnancy, thus reducing other direct and indirect cots related to PLBP.

Primary Outcome. Number and % of days during pregnancy with maximum pain ≤ 4/10.

Secondary Outcomes. Pain scale 4 weeks after inclusion, mean Oswestry disability score between inclusion and delivery, direct costs related to pregnancy care and pain management, indirect costs related to impairment throughout pregnancy and the immediate postpartum.

Method. Multicenter randomized trial with parallel groups. Intervention: 5 acupuncture sessions over 4 weeks, plus standard treatment. Controls: standard treatment.

Analysis per pregnancy Follow up: logbook kept by he patient plus analysis of obstetrical records. Number of patients: 300 Inclusion criteria: singleton uncomplicated 16-34 weeks pregnancy, with PLBP \> 4/10 Exclusion criteria Obstetrical complication other than PLBP, contra indication to acupuncture, sciatica, maternal age \< 18, no health insurance.

Duration. Overall duration: 3 years and 6 months, inclusions over 3 years. Duration of inclusion per patient: 2-26 weeks Number of participating centers 5

Eligibility Criteria:
Inclusion Criteria:

* singleton uncomplicated 16-34 weeks pregnancy, with PLBP \> 4/10

Exclusion Criteria:

* Obstetrical complication other than PLBP,
* contra indication to acupuncture,
* sciatica
* maternal age \< 18
* no health insurance.
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.

The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).

Eligibility Criteria:
Inclusion Criteria:

* Age greater than or equal to 18 years old;
* chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
* refractory and/or relapsed disease during or after venetoclax treatment;
* tumor samples available.
* Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
* Patients must be able to express their opposition to be enrolled in this study, if need be.
* Patients must be affiliated at the French Social Security system

Exclusion Criteria:

Patients of their legal guardians refusing to participate

-
RDEA3170 Bioavailability Study

This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets) and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat and high-fat meal on the PK and PD of RDEA3170 10 mg tablets.


Eligibility Criteria:
Inclusion Criteria:

* Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity
* Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2
* Subject has a Screening serum urate level ≤ 7 mg/dL
* Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment

Exclusion Criteria:

* Subject has a history or suspicion of kidney stones
* Subject has undergone major surgery within 3 months prior to Screening
* Subject donated blood or experienced significant blood loss (\> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1
* Subject has inadequate venous access or unsuitable veins for repeated venipuncture
* Subject has a Screening serum creatinine value above the upper limit of normal during Screening or at Day -2 (Admission)
* Subject cannot swallow multiple tablets
* Subject is a heavy caffeine drinker
* Subject is unwilling to comply with the dietary restrictions of the study
* Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease

The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using both GERD questionnaire and clinical symptoms assessment

A prospective, observational study to describe symptom control and impact on daily life in patients with gastroesophageal reflux disease (GERD)

Eligibility Criteria:
Inclusion Criteria:

* Patients known or newly diagnosed with GERD
* Patients with typical GERD symptoms as heartburn and regurgitation for ≥2 days in the previous week
* Patients, currently not treated with a proton pump inhibitor

Exclusion Criteria:

* Patients who have been receiving treatment with non-steroidal antiinflammatory drugs within two weeks prior the inclusion in the study
* Patients with medical history of surgery of the esophagus, stomach or duodenum
* Pregnant or nursing females
The Effects of HIV Protease Inhibitors in Severe Sepsis

Sepsis is the leading cause of death in critically ill patients in the United States. It develops in approximately 750,000 Americans annually, and more than 210,000 of them die. Despite improvements in supportive treatment, mortality has changed very little, and until recently, no sepsis-specific treatments were available. Protease inhibitors have seemed to have an immune benefit that extends beyond their ability to prevent HIV replication. T cells in those patients treated with protease inhibitors have reduced rates of death than in those patients not receiving therapy.

Our hypothesis is that protease inhibitor therapy will prevent apoptosis associated with sepsis, and this will be manifested as improved clinical outcome, as assessed by 28-day mortality, APACHE II and III, and SOFA scores. All patients enrolled in the study will receive the standard of care for sepsis at Mayo Clinic Rochester. Patients will receive 1250 mg of Nelfinavir/placebo twice each day for seven days with regularly scheduled blood draws (Days 0, 4, and 7).

Eligibility Criteria:
Infection criteria:known or suspected infection, as evidenced by one or more of the following: WBC in normally sterile body fluid, radiographic evidence of pneumonia, a syndrome associated with a high risk of infection.

Modified SIRS criteria: must meet three or more of the following four criteria: a temperature higher than 38C or lower than 36C, heart rate of more than 90 beats/minute, respiratory rate of more than 20 breaths/minute (or on a mechanical ventilator), WBC more than 12,000/mm(3) or less than 4,000/mm(3).

Dysfunctional organs criteria:must meet one or more of the following five criteria:cardiovascular system dysfunction, kidney dysfunction, respiratory dysfunction, hematological dysfunction, unexplained metabolic acidosis.
Randomized Trial on Scarpa Fascia Preservation During Hernio-abdominoplasty

This randomized trial aimed to assess the efficacy of preservation of Scarpa's fascia during hernio-abdominoplasty in reducing the volume of postoperative drainage, accelerating time to drain removal and recovery, and reducing complication rate.


Eligibility Criteria:
Inclusion Criteria:

* Patients with complex ventral hernia that are fit for surgery (ASA class I and II) (Saklad, 1941).
* Patients with class III, IV according to Pitanguy's classification of abdominal deformities (Pitanguy, 1995).

Exclusion Criteria:

1. Patient with ASA class III, IV, and V.
2. Morbid obesity (BMI \> 40).
3. Recurrent incisional hernias after mesh hernioplasty.
4. Strangulated hernias.
5. Isolated small paraumbilical hernias.
6. Patients with abdominal organomegaly and/or ascites.
7. Patients with coagulopathy,
8. Patients who are heavy smokers, patients with pulmonary problems, and patients with uncontrolled diabetes.
Scheimpflug Versus Placido-disc System in Evaluation of Corneal Higher-Order Aberrations

Aim of work:

To assess the agreement between placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam ) regard measuring corneal higher order aberrations before and after LASIK.

Higher-order aberrations (HOAs) are small optical irregularities of the eye, which can have an impact on the quality of the retinal image. In contrast to lower order aberrations, these errors cannot be corrected with regular spectacles and most contact lenses. Additionally, HOAs are responsible for an array of visual symptoms including dysphotopsia, glare, as well as a reduction in contrast sensitivity. The cornea accounts for approximately 90% of ocular aberrations.Advances and breakthroughs in wavefront aberration measurement technology can help clinicians to better understand and manage corneal higher-order aberrations (HOAs), especially for the preoperative planning of corneal refractive surgery and cataract surgery.A recent study has shown that corneal HOAs can be a sensitive parameter to differentiate early keratoconus from normal eyes. Furthermore, corneal aberrations have been widely used to evaluate dry eye and orthokeratology.LASIK surgery is widely used in the correction of refractive errors It is well known that LASIK surgery induces high-order aberrations (HOA) .The main eye element involved in the generation of such aberrations is the first corneal surface. Currently, devices based on Placido-disc, Hartmann- Shack, ray tracing, or Scheimpflug are routinely used in clinical aberration measurement. Of which Pentacam is one of common instruments that can only measure corneal aberration (including anterior and posterior corneal surface) based on Scheimpflug technology. Also Allegro Topolyzer is a Placido-based topographer that can measure anterior corneal higher order aberrations (HOAs). A better understanding of the agreement of device measurements can provide clinicians with useful information for measuring, correcting, and monitoring aberrations around refractive and cataract surgery. Investigators , therefore, aimed to study the agreement between the two instruments in anterior corneal aberration measurement.

Eligibility Criteria:
Inclusion Criteria:

* Patients with refractive errors from +6 diopters to -8 diopters sphere and up to -6diopters cylinder.

Exclusion Criteria:

* Patients with systemic diseases such as diabetes.
* keratoconus or keratoconus suspect, amblyopic eyes.
* Patients with best corrected visual acuity (BCVA) not achieving 20/25.
* glucoma
* Previous ocular surgeries or trauma.
Atherectomy and Drug Coated Balloon for the Treatment of Arterio-Venous Graft Stenosis

This single-centre, single-arm, prospective study will enroll 30 subjects presenting with clinical and hemodynamic abnormalities in arteriovenous graft (AVG) in the arm. Subjects will be treated with the Jetstream™ atherectomy device and Ranger™ Drug Coated Balloons (DCB). Subjects will be followed up clinically via office visit or phone visit at 6 and 12 months post procedure. This study is to demonstrate safety and assess the clinical use and outcomes of the Jetstream ™atherectomy device and Ranger™ DCB for the treatment of dysfunctional AV graft.


Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant, non-breastfeeding female ≥18 years of age;
* Subject is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits;
* Target lesion must be a mature arteriovenous graft presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines;
* Subject has a target lesion at the venous anastomosis of the AVG;
* Successful crossing of the stenosis;
* Each lesion length is ≤20mm, which may include tandem lesions that are ≤20mm apart

Exclusion Criteria:

* Subject is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this study;
* Subject has a non-controllable allergy to contrast;
* Subject has more than 3 lesions in the access circuit requiring intervention;
* Target lesion diameter \>10mm;
* A thrombosed access or an access with a thrombosis treated ≤30 days prior to the index procedure;
* Prior surgical interventions of the access site ≤30 days before the index procedure;
* Target lesion is located within a bare metal or covered stent.
Establishment of a Database of Patients Suffering From Obesity With a Medical Treatment

Obesity is a public health problem, given its prevalence (15% in France in 2012, Obépi survey) but also by the complications that it generates. We were firstly, intersted in bone mineral density during obesity.

We were able to confirm in an observational study that BMD (Z-score)was augmented. We also showed, for the first time, that this increase in Z-score was dependent on sex, severity of obesity and age but also bone site. If the increase in BMD at the level of the bearing zones seems logically to be explained by the hypothesis that the mechanical stresses have an osteogenic effect on the bone tissue, the latter can not in any way respond to the concomitant increase in BMD at non-bearing areas such as the radius.These results suggest that changes in certain systemic compounds induced by obesity may interfere with bone metabolism. recent data also suggest a change in the concentration of pro-glucagon peptides (GLP-1, glicentin, glucagon, etc.) in obese subjects and in bariatric surgery). Although body composition and its variation after surgery could be largely involved in the modification of these peptides, no data on these potential relationships is currently available. However, no data are available for baseline body composition and weight loss data. Finally, 80% of obesity is associated with insulin resistance, a key mechanism in the pathophysiology of type 2 diabetes. A metabolically healthy obesity phenotype is described, although the definition criteria are not consensual.The evolution of this phenotype with aging and with the duration of evolution of obesity is not well described.

Our goal is to create a database of weight-bearing patients in the care setting and to determine the "hormonal dialogue" between peripheral (muscular and adipose) and bone tissues, which may be associated with changes in body composition during obesity and aging, and that according to sex.


Eligibility Criteria:
Inclusion criteria:

- obese patients age above 18 years old

Exclusion criteria:

- non agreement of inclusion
Scoliosis Survey to Development Treatment Decision Tool

This is a survey to help understand the influences related to the decision for Adolescent Idiopathic Scoliosis treatment (observation vs. bracing vs. surgery). The investigator then plans to create a decision aid to help families when making a decision about the treatment choice being presented to them.

This survey is designed to help understand the factors that families consider to help make treatment decisions related to Adolescent Idiopathic Scoliosis (AIS). The surveys will then be used to help create a shared decision making tool to help families better understand the treatment options and optimize clinical conversations surrounding AIS treatment.

Eligibility Criteria:
Inclusion Criteria:

* Subject (and/or parent of subject) who has previously been treated for Adolescent Idiopathic Scoliosis (AIS)

Exclusion Criteria:

* Age less than or equal to 12 years
Ultrasound Greater Occipital Nerve Block at C2 Level Compared to Landmark-based Greater Occipital Nerve Block

This study will compare the analgesic benefit of a traditional landmark-guided GON block with the ultrasound-guided approach over a four week period in patients with occipital neuralgia or cervicogenic headache.

Hypothesis: A novel ultrasound-guided greater occipital nerve (GON) block at the level of C2 will result in significantly lower pain scores after 4 weeks when compared with a traditional landmark-guided approach at the superior nuchal line.

The greater occipital nerve (GON) has been implicated in several conditions that prompt referral to pain medicine specialists, including occipital neuralgia and cervicogenic headache. According to the International Headache Society, a local anesthetic block of the GON can aid in the diagnosis and treatment of occipital neuralgia. Many practitioners perform GON injections using a conventional approach, relying solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line. The ambiguity of these injections poses a risk of anesthetizing adjacent structures or injecting into vessels, such as the occipital artery.

In an attempt to mitigate these risks and improve the efficacy of GON injections, ultrasound has been increasingly utilized. Multiple studies have demonstrated successful ultrasound-guided GON blockade at the superior nuchal line and improvement in pain scores compared to non-guided injections. The investigators' preliminary data confirms the feasibility, efficacy, and safety of an ultrasound-guided GON block technique at the level of C2, but it is not yet known whether this technique provides greater pain relief and functional outcomes compared to traditional injections.

Eligibility Criteria:
Inclusion Criteria:

1. Unilateral or bilateral headache symptoms attributed to occipital neuralgia or cervicogenic headache as defined by the International Headache Society's International Classification of Headache Disorders (3rd edition beta version)
2. Age 18 years and older (no upper age limit defined)
3. Imaging of cervical spine within last year (either x-ray, MRI or CT)

Exclusion Criteria:

1. History of cervical spine surgery, trauma, or surgical procedure involving head or neck during the last year
2. Use of new preventative medications 1 month prior or during study enrollment
3. Evidence of impaired sensation in the GON dermatome region (posterior scalp to the vertex of the cranium) from neurological, dermatological, or other disease process
4. Evidence of cranial defect or other anatomical abnormality near the target injection site
5. History of bleeding diathesis, coagulopathy, or current use of anticoagulant medications
6. Pregnancy
7. History of adverse reaction or allergy to local anesthetic agents or corticosteroids
8. Occipital nerve block within the past three months.
9. Unavailability for appropriate follow-up throughout the whole duration of study
Shear Wave Elastography New Ultrasound Approach for the Erectile Dysfunction

the study proposes the use of a new non-invasive ultrasound method for the diagnosis of erectile dysfunction. in particular, the shear Wave elastosonosgraphy of the corpora cavernosa will be used. this last method quantitatively measures the rigidity of the analyzed tissues.

erectile function is a complex mechanism in which the elasticity of the tissues that make up the corpora cavernosa is fundamental. indeed, anatomopathological studies have shown that in patients with erectile dysfunction the elastic fibers are replaced by inextensible collagen. the aim of the study is the correlation between penile stiffness measured with this new non-invasive diagnostic method - elastosonography of the corpora cavernosa - and the correlation with validated questionnaires. the international Index of Erectile Function (IIEF5) short form and the erectile Hardness Score (EHS) will be used.

Eligibility Criteria:
Inclusion Criteria:

male who came attended our general andrology clinic between January 2019 to January 2020.

Exclusion Criteria:

1. with: age \>80 years or \<18 years. , 2
2. diabetes,
3. spinal trauma,
4. treatment with continuous PDE5i,
5. ischemic heart disease for less than 6 months,
6. pelvic surgery for within less than 1 year,
7. hypotestosteronemia (\<8 nmol/L),
8. La Peyronie's disease.
9. penile trauma.